GME
GameStop Corp.
GME's fundamentals are strong: its operating margin rose 11 points to 14% and it turned 19% of its revenue into free cash flow, though revenue fell 7.7%. At 17x earnings, it's trading less than half its usual 44x. Analysts expect earnings to fall sharply.
NCI
Neo-Concept International Group Holdings Limited
There isn't enough reported data to score NCI yet.
GME Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Unavailable |
GME's profitability and cash flow are currently strong, and its revenue is stable. There isn't enough data to rate its balance sheet.
NCI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Stable | |
| Unavailable | |
| Strong |
NCI's balance sheet is currently strong, and its profitability is stable. There isn't enough data to rate its revenue and cash flow.
GME PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 17x | $25.62 | — |
| Cheap | 18x | $27.96 | +9.1% |
| Forward | 38x | $25.62 | — |
| Fair | 43x | $66.84 | +161% |
| Expensive | 252x | $388 | +1414% |
Historical ranges are pointers, not guarantees.
GME has the edge over NCI in the historical PE scenario, which offers more potential upside but is not a forecast.
NCI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.5x | $4.21 | -18% |
| Current | 7.9x | $5.12 | — |
| Fair | 13x | $8.38 | +64% |
| Expensive | 107x | $69.87 | +1265% |
Historical ranges are pointers, not guarantees.
NCI's PE is 7.8x, but its earnings don't support one, so it isn't a reliable read right now.
GME Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect GME's earnings and revenue to decline, with profitability weakening.
NCI Forward outlook
There aren't enough analyst estimates for NCI to show an outlook.
GME Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.67 | -56% |
| Q3 2026 | $1.54 | +93% |
| Q2 2026 | $1.34 | +153% |
| Q1 2026 | $0.77 | +133% |
| Q4 2025 | $0.89 | +394% |
| Q3 2025 | $0.80 | +515% |
| Q2 2025 | $0.53 | +563% |
| Q1 2025 | $0.33 | +1550% |
| Q4 2024 | $0.18 | +$0.21 |
GME has the edge over NCI in the latest year-over-year earnings comparison.
NCI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.65 | -96% |
| Q4 2024 | $16.71 | +64% |
| Q4 2023 | $10.19 | -64% |
| Q4 2022 | $28.08 | +128% |
NCI's earnings per share have fallen from their peak: $0.65 over the past year, against $35.52 in mid-2022.
GME Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $790.2M | -19% |
| Q2 2026 | $835.3M | +14% |
| Q1 2026 | $1.1B | -14% |
| Q4 2025 | $821M | -4.6% |
| Q3 2025 | $972.2M | +22% |
| Q2 2025 | $732.4M | -17% |
| Q1 2025 | $1.3B | -28% |
| Q4 2024 | $860.3M | -20% |
NCI has the stronger quarterly revenue trend. Revenue is down 19% for GME versus up 77% for NCI.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +13 points |
| Q2 2026 | 17% | +19 points |
| Q1 2026 | 12% | +6 points |
| Q4 2025 | 5% | +8.9 points |
| Q3 2025 | 6.8% | +9.6 points |
| Q2 2025 | -1.5% | +4.3 points |
| Q1 2025 | 6.2% | +3.1 points |
| Q4 2024 | -3.9% | -2.5 points |
GME's operating margin was 20% last quarter, up 13 points from the same quarter a year ago, near the top of its range since 2019.
NCI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $17.5M | -42% |
| Q4 2024 | $30M | +35% |
| Q4 2023 | $22.2M | +125% |
| Q4 2022 | $9.9M | -7.4% |
| Q3 2022 | $9.9M | -7.4% |
| Q2 2022 | $12.2M | +164% |
| Q1 2022 | $12.2M | +164% |
NCI's revenue is growing: $17M last quarter, up 77% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 1.3% | -1.6 points |
| Q4 2024 | 4.9% | -2.5 points |
| Q4 2023 | 5.2% | -2.3 points |
| Q4 2022 | 3% | -0.4 points |
| Q3 2022 | 3% | -0.4 points |
| Q2 2022 | 7.5% | +9 points |
| Q1 2022 | 7.5% | +9 points |
| Q4 2021 | 3.3% | N/A |
NCI's operating margin was 1.3% last quarter, down 1.6 points from the same quarter a year ago.
GME Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $60.7M | -46% |
| Q2 2026 | $332.9M | +76% |
| Q1 2026 | $187.4M | +18% |
| Q4 2025 | $107M | +435% |
| Q3 2025 | $113.3M | +73% |
| Q2 2025 | $189.6M | +$304.3M |
| Q1 2025 | $158.8M | +$177.5M |
| Q4 2024 | $20M | +80% |
GME has the stronger cash trend. Its trailing FCF is up 2,081% versus its history, compared with NCI at down 156%.
NCI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $2.2M | +$2.7M |
| Q4 2024 | -$473.3K | +$6M |
| Q4 2023 | -$6.4M | -$1.6M |
| Q4 2022 | -$4.8M | -883% |
| Q3 2022 | -$4.8M | -883% |
| Q2 2022 | $2.1M | +5597% |
| Q1 2022 | $2.1M | +5597% |
NCI's free cash flow was −$9M over the past year, against −$45,684 the year before.
GME Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +300K shares |
| 1 year | +8.4% | +46.1M shares |
| 3 years | +94% | +288M shares |
| 5 years | +104% | +302M shares |
| Available history | +80% | +264M shares |
GME has the edge over NCI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q1 2020 | $21.8M |
| Q4 2019 | $114M |
NCI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.7% | +2.2K shares |
| 1 year | +13% | +7.3K shares |
NCI has 63,500 diluted shares, up 13% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
GME Net Leverage
NCI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 0.4x | Very low |
| Q4 2024 | 1.3x | Healthy |
| Q4 2023 | 2.7x | Moderate |
| Q4 2022 | 4.0x | Elevated |
| Q2 2022 | 1.4x | Healthy |
| Q4 2021 | 5.8x | High |
NCI's net debt is less than a year of its operating earnings (EBITDA), down from 1.4 years a year ago.
GME Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.9 | Neutral |
| Stochastic | 68.5 | Neutral |
GME's weekly RSI is 60 (neutral) and its Stochastic is 69 (neutral).
NCI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.9 | Neutral |
| Stochastic | 1.9 | Oversold |
NCI's weekly RSI is 34 (neutral) and its Stochastic is 2 (oversold).
GME PE vs Consumer Cyclical Sector
| Metric | GME | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 18x | 7.7% below |
| PE % | 15 | 47 | 32 pts below |
GME is trading at 17x earnings, in line with the Consumer Cyclical sector's median of 18x.
NCI PE vs Consumer Cyclical Sector
| Metric | NCI | Sector median | Relative |
|---|---|---|---|
| PE | 7.9x | 18x | 56% below |
| PE % | 34 | 24 | 10 pts above |
NCI has the edge over GME on valuation relative to its sector.
GME Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.2 | 1.8% above |
| 20 week MA | $22.4 | 15% above |
| 50 week MA | $22.6 | 13% above |
| 100 week MA | $24.0 | 7% above |
| 200 week MA | $21.8 | 17% above |
GME has stronger trend alignment. GME is above 5 of 5 weekly averages versus NCI above 0 of 4.
NCI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.7 | 74% below |
| 20 week MA | $67.8 | 92% below |
| 50 week MA | $117.5 | 96% below |
| 100 week MA | $125.3 | 96% below |
NCI is in a downtrend: it's below all four of its weekly moving averages, and 96% below its 100-week average.
GME Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.48 | $5.04 | +241% |
| 2021 | $5.04 | $38.0 | +655% |
| 2022 | $38.0 | $20.1 | -47% |
| 2023 | $20.1 | $17.5 | -13% |
| 2024 | $17.5 | $32.2 | +84% |
| 2025 | $32.2 | $21.1 | -35% |
| 2026 YTD | $21.1 | $25.6 | +21% |
GME has the edge over NCI on returns for 2026, with the stronger performance.
NCI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $601.6 | $167.0 | -72% |
| 2025 | $167.0 | $78.1 | -53% |
| 2026 YTD | $78.1 | $5.12 | -93% |
NCI has finished every year since 2024 lower, and it's down 93% so far in 2026.